Advertisement
Australia markets open in 8 hours 1 minute
  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     
  • AUD/USD

    0.6506
    +0.0006 (+0.09%)
     
  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     
  • OIL

    82.48
    -0.33 (-0.40%)
     
  • GOLD

    2,342.50
    +4.10 (+0.18%)
     
  • Bitcoin AUD

    98,445.95
    -909.99 (-0.92%)
     
  • CMC Crypto 200

    1,382.45
    -0.13 (-0.01%)
     

Did You Acquire (EBS) Before April 24, 2020? Johnson Fistel Investigates Emergent; Should Management be Held Accountable for Investors Losses?

SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) --

Johnson Fistel, LLP is investigating potential claims on behalf of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE: EBS) against certain of its officers and directors.

If you are a current shareholder of Emergent, holding shares before April 24, 2020, you may have standing to hold Emergent harmless from the alleged harm caused by the Company's officers by making them personally responsible. You may also be able to assist in reforming the Company's corporate governance to prevent future wrongdoing.

Click here to join this action

ADVERTISEMENT

A Securities Class Action Complaint was filed on behalf of those who purchased securities of Emergent from April 24, 2020 and April 16, 2021.

According to the filed complaint: (i) Emergent's Baltimore plant had a history of manufacturing issues increasing the likelihood for massive contaminations; (ii) these longstanding contamination risks and quality control issues at Emergent's facility led to a string of FDA citations; (iii) the Company previously had to discard the equivalent of millions of doses of COVID-19 vaccines after workers at the Baltimore plant deviated from manufacturing standards; and (iv) as a result of the foregoing, Defendants' public statements about Emergent's ability and capacity to mass manufacture multiple COVID-19 vaccines at its Baltimore manufacturing site were materially false and misleading and lacked a reasonable basis.

If you are interested in learning more about the investigation, please contact lead analyst Jim Baker (jimb@johnsonfistel.com) at 619-814-4471. If emailing, please include a phone number.

Additionally, if you are a current, long-term shareholder of Emergent, holding shares before April 24, 2020, you can [Click here to join this action]. There is no cost or obligation to you.

About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.